Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

214results about How to "Lower cost of care" patented technology

Sensor Systems for Drug Delivery Devices

Systems for drug delivery devices include a temperature control system and an identification system. A temperature control system configured to sense and control temperature of a cartridge containing a drug includes a heater, one or more temperature sensors, and a control unit. An identification system configured to identify a cartridge containing a drug includes a control unit and a tag sensor that is electrically coupled to the control unit, wherein the tag sensor is activated upon detecting a presence of the cartridge. A drug delivery device includes both the temperature control system and the identification system such that the control unit of the device may process the information of the drug that is received from the tag sensor of the identification system, and based on at least a portion of the processed information, determine and control the temperature of the drug within a cartridge.
Owner:UN HOLDINGS LLC

Method for production of medical records and other technical documents

A computer implemented system for the production of medical records, legal documents and other frequently produced semi-technical documents. This is accomplished by generating an intelligent computer-guided interview and the use of serialized scriptable objects. Major program elements include a knowledge base text file, a parse engine, and an execution module. The knowledge base uses a unique rule syntax. The parse engine converts the textual knowledge base file to a compiled binary representation which can then be interpreted by the execution module. The execution module leads the user through the interview by generating a series of questions and presents possible answers in the form of pick lists. The data is recorded with a computer pen and collated into a document file. This file is coded in binary format and can be written to and recalled from disk. If the file is recalled from disk the user can continue to answer questions or change answers previously given. The result is a mobile computing system whereby data is input in a structured format. When the program is executed the user is prompted for answers to questions and, based upon the user's response, the final document can change considerably. Depending upon each answer, the program may change the subsequent questions being asked, change the list associated with a question, change the text being generated, or change the entire structure of the document. The data collected may be also be stored in a database for analysis at a later date. Finally, the data collected is output in a narrative text format which can be tailored according to the traditions and expectations of the user's profession. The program will output the text via a printer or it can be transmitted via electronic means.
Owner:MITCHELL GEOFFREY C +1

Method, system and device for treating disorders of the pelvic floor by means of electrical stimulation of the pudendal and associated nerves, and the optional delivery of drugs in association therewith

ActiveUS7328068B2Undesirable side effects of sacral nerve stimulation may be avoided or minimizedUndesirable side-effectDigestive electrodesGenital electrodesDiseaseProstatalgia
Described are implantable devices and methods for treating various disorders of the pelvic floor by means of electrical stimulation of the pudendal or other nerves, and optional means for delivering drugs in association therewith. A method of precisely positioning and implanting a medical electrical lead so as to provide optimal stimulation of the pudendal nerve or a portion thereof is also described. Placement of a stimulation lead next to or on the pudendal nerve may be performed using conventional prior art techniques through gross anatomical positioning, but usually does not result in truly optimal lead placement. One method of the present invention utilizes neurophysiological monitoring to assess the evoked responses of the pudendal nerve, and thereby provide a method for determining the optimal stimulation site. Additionally, one or more electrical stimulation signals are applied, and optionally one or more drugs are infused, injected or otherwise administered, to appropriate portions of a patient's pelvic floor and pudendal nerve or portions thereof in an amount and manner effective to treat a number of disorders, including, but not limited to, urinary and / or fecal voiding dysfunctions such as constipation, incontinence disorders such as urge frequency and urinary retention disorders, sexual dysfunctions such as orgasmic and erectile dysfunction, pelvic pain, prostatitis, prostatalgia and prostatodynia.
Owner:MEDTRONIC INC

Method, system and device for treating disorders of the pelvic floor by means of electrical stimulation of the pudenal and associated nerves, and the optional delivery of drugs in association therewith

Described are implantable devices and methods for treating various disorders of the pelvic floor by means of electrical stimulation of the pudendal or other nerves, and optional means for delivering drugs in association therewith. A method of precisely positioning and implanting a medical electrical lead so as to provide optimal stimulation of the pudendal nerve or a portion thereof is also described. Placement of a stimulation lead next to or on the pudendal nerve may be performed using conventional prior art techniques through gross anatomical positioning, but usually does not result in truly optimal lead placement. One method of the present invention utilizes neurophysiological monitoring to assess the evoked responses of the pudendal nerve, and thereby provide a method for determining the optimal stimulation site. Additionally, one or more electrical stimulation signals are applied, and optionally one or more drugs are infused, injected or otherwise administered, to appropriate portions of a patient's pelvic floor and pudendal nerve or portions thereof in an amount and manner effective to treat a number of disorders, including, but not limited to, urinary and/or fecal voiding dysfunctions such as constipation, incontinence disorders such as urge frequency and urinary retention disorders, sexual dysfunctions such as orgasmic and erectile dysfunction, pelvic pain, prostatitis, prostatalgia and prostatodynia.
Owner:MEDTRONIC INC

Medical scoring systems and methods

InactiveUS20130185097A1Great sensitivity and specificityImprove parental counselingData processing applicationsHealth-index calculationObservation dataICU scoring systems
Systems and methods for generating a medical score are disclosed. In some embodiments, an accurate medical score is generated within a relatively short period of time. The medical score can be derived from observational data and / or physiological time-series data collected from a subject. In some embodiments, a scoring system accesses the data, and at least a portion of the data is used in the calculation of the medical score. In certain embodiments, health care providers can use the medical score to make early predictions of complications in intensive care unit patients.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories

InactiveUS20040185478A1Reduce usageDetermine rapidly the bacterial resistance to antibioticsMicrobiological testing/measurementFermentationBacteroidesNeisseria meningitidis
DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample DNA from (i) any bacterium, (ii) the species Streptococcus agalactiae, Staphylococcus saprophyticus, Enterococcus faecium, Neisseria meningitidis, Listeria monocytogenes and Candida albicans, and (iii) any species of the genera Streptococcus, Staphylococcus, Enterococcus, Neisseria and Candida are disclosed. DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample antibiotic resistance genes selected from the group consisting of blatem, blarob, blashv, blaoxa, blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6'-lla, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6')-aph(2''), aad(6'), vat, vga, msrA, sul and int are also disclosed. The above microbial species, genera and resistance genes are all clinically relevant and commonly encountered in a variety of clinical specimens. These DNA-based assays are rapid, accurate and can be used in clinical microbiology laboratories for routine diagnosis. These novel diagnostic tools should be useful to improve the speed and accuracy of diagnosis of microbial infections, thereby allowing more effective treatments. Diagnostic kits for (i) the universal detection and quantification of bacteria, and / or (ii) the detection, identification and quantification of the above-mentioned bacterial and fungal species and / or genera, and / or (iii) the detection, identification and quantification of the above-mentioned antibiotic resistance genes are also claimed.
Owner:GENEOHM SCI CANADA

System and method for distributing healthcare products

A system and method for distributing healthcare products is disclosed. A patient who obtains a prescription from clinic such as a federally qualified 340B health clinic (FQHC) is entered into a retail pharmacy's computer as a third party patient. Prescription information is transmitted to a healthcare product distributor inventory tracking system where the retail pharmacy is credited at its original invoice cost for the product. The healthcare product distributor's system charges the FQHC for the product at the 340B price. The inventory system tracks each 340B product distributed. In some cases, the first time a product is dispensed, the FQHC is charged for a stock package size and subsequent prescriptions are tracked and applied against the original purchase until the amount dispensed equals or exceeds the stock package originally charged to the FQHC. Once the quantity dispensed exceeds the stock package size, the inventory accumulation process is restarted.
Owner:FIACCO JOHN +2

Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories

InactiveUS20060263810A1Reduce usageDetermine rapidly the bacterial resistance to antibioticsSugar derivativesMicrobiological testing/measurementNeisseria meningitidisListeria monocytogenes
DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample DNA from (i) any bacterium, (ii) the species Streptococcus agalactiae, Staphylococcus saprophyticus, Enterococcus faecium, Neisseria meningitidis, Listeria monocytogenes and Candida albicans, and (iii) any species of the genera Streptococcus, Staphylococcus, Enterococcus, Neisseria and Candida are disclosed. DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample antibiotic resistance genes selected from the group consisting of blatem, blarob, blashv, blaoxa, blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6′-IIa, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6′)-aph(2″), aad(6), vat, vga, msrA, sul and int are also disclosed. The above microbial species, genera and resistance genes are all clinically relevant and commonly encountered in a variety of clinical specimens. These DNA-based assays are rapid, accurate and can be used in clinical microbiology laboratories for routine diagnosis. These novel diagnostic tools should be useful to improve the speed and accuracy of diagnosis of microbial infections, thereby allowing more effective treatments. Diagnostic kits for (i) the universal detection and quantification of bacteria, and / or (ii) the detection, identification and quantification of the above-mentioned bacterial and fungal species and / or genera, and / or (iii) the detection, identification and quantification of the above-mentioned antibiotic resistance genes are also claimed.
Owner:GENEOHM SCI CANADA

Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories

DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample DNA from (i) any bacterium, (ii) the species Streptococcus agalactiae, Staphylococcus saprophyticus, Enterococcus faecium, Neisseria meningitidis, Listeria monocytogenes and Candida albicans, and (iii) any species of the genera Streptococcus, Staphylococcus, Enterococcus, Neisseria and Candida are disclosed. DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample antibiotic resistance genes selected from the group consisting of blatem, blarob, blashv, blaoxa, blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6'-lla, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6')-aph(2''), aad(6'), vat, vga, msrA, sul and int are also disclosed. The above microbial species, genera and resistance genes are all clinically relevant and commonly encountered in a variety of clinical specimens. These DNA-based assays are rapid, accurate and can be used in clinical microbiology laboratories for routine diagnosis. These novel diagnostic tools should be useful to improve the speed and accuracy of diagnosis of microbial infections, thereby allowing more effective treatments. Diagnostic kits for (i) the universal detection and quantification of bacteria, and/or (ii) the detection, identification and quantification of the above-mentioned bacterial and fungal species and/or genera, and/or (iii) the detection, identification and quantification of the above-mentioned antibiotic resistance genes are also claimed.
Owner:BERGERON MICHEL G +3
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products